CONCLUSIONS: Comorbid MDD is associated with substantial shifts in ADHD medication prescribing toward non-stimulants, yet CNS stimulants were associated with the most favorable clinical outcomes, with bupropion emerging as a clinically meaningful alternative when a non-stimulant is considered. These findings should be validated in future longitudinal prospective studies and randomized clinical trials.
